Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
AstraZeneca
Daiichi Sankyo
Chubb
Cantor Fitzgerald
Argus Health

Generated: May 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,713,999

« Back to Dashboard

Summary for Patent: 7,713,999
Title:Thrombin receptor antagonists
Abstract: Heterocyclic-substituted tricyclics of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represents an optional double bond, n is 0-2; Q is cycloalkyl, optionally substituted by R.sup.13 and R.sup.14; R.sup.13 and R.sup.14 are independently selected from (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl, --OH, (C.sub.1-C.sub.6)alkoxy, R.sup.27-aryl(C.sub.1-C.sub.6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R.sup.13 and R.sup.14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms, Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
Inventor(s): Chackalamannil; Samuel (Califon, NJ), Clasby; Martin C. (Plainsboro, NJ), Greenlee; William J. (Teaneck, NJ), Wang; Yuguang (North Brunswick, NJ), Xia; Yan (Edison, NJ), Veltri; Enrico P. (Princeton, NJ), Chelliah; Mariappan V. (Edison, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:11/733,635
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,713,999
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 7,713,999

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aralez Pharms ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD) ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,713,999

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 028952 ➤ Try a Free Trial
Argentina 039570 ➤ Try a Free Trial
Argentina 045809 ➤ Try a Free Trial
Argentina 047088 ➤ Try a Free Trial
Argentina 098260 ➤ Try a Free Trial
Austria 368659 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Federal Trade Commission
Chinese Patent Office
Deloitte
Healthtrust
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.